Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 31104, Gt
2. Cholestagel
3. Colesevelam Hcl
4. Colesevelam Hydrochloride
5. Gt 31104
6. Gt-31104
7. Gt31 104
8. Gt31-104
9. Gt31104
10. Hcl, Colesevelam
11. Hydrochloride, Colesevelam
12. Welchol
1. Welchol
2. Colesevelam Hcl
3. 2-(chloromethyl)oxirane;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;chloride;hydrochloride
4. Gt 31-104hb
5. Unii-p4sg24wi5q
6. Gt-31104
7. Gt 31-104
8. Colesevelam Hydrochloride [usan]
9. P4sg24wi5q
10. Gt31-104hb
11. Cholestagel, Colesevelam Hydrochloride
12. Akos037653488
13. Hs-0084
14. Nsc 760126
15. 1-hexaminium, N,n,n-trimethyl-6-(2-propenylamino)-, Chloride, Polymer With (chloromethyl)oxirane, 2-propen-4-amine And N-2-propenyl-1-decanamine, Hydrochloride
16. 2-propen-1-amine Polymer With (chloromethyl)oxirane, N,n,n-trimethyl-6-(2-propenylamino)-1-hexanaminium Chloride, And N-2-propenyl-1-decanamine, Hydrochloride
17. Allylamine Polymer With 1-chloro-2,3-epoxypropane, (6-(allylamino)hexyl)trimethylammonium Chloride And N-allyldecylamine, Hydrochloride
18. Ft-0697863
19. Ab01563397_01
20. Q899036
| Molecular Weight | 618.2 g/mol |
|---|---|
| Molecular Formula | C31H67Cl3N4O |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 22 |
| Exact Mass | 616.438046 g/mol |
| Monoisotopic Mass | 616.438046 g/mol |
| Topological Polar Surface Area | 62.6 Ų |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 301 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 6 |
| 1 of 2 | |
|---|---|
| Drug Name | Welchol |
| PubMed Health | Colesevelam (By mouth) |
| Drug Classes | Antihyperlipidemic |
| Drug Label | WELCHOL (colesevelam hydrochloride) is a non-absorbed, polymeric, lipid-lowering and glucose-lowering agent intended for oral administration. Colesevelam hydrochloride is a high-capacity bile acid-binding molecule. Colesevelam hydrochloride is poly(a... |
| Active Ingredient | Colesevelam hydrochloride |
| Dosage Form | Tablet; For suspension |
| Route | Oral |
| Strength | 625mg; 1.875gm/packet; 3.75gm/packet |
| Market Status | Prescription |
| Company | Daiichi Sankyo |
| 2 of 2 | |
|---|---|
| Drug Name | Welchol |
| PubMed Health | Colesevelam (By mouth) |
| Drug Classes | Antihyperlipidemic |
| Drug Label | WELCHOL (colesevelam hydrochloride) is a non-absorbed, polymeric, lipid-lowering and glucose-lowering agent intended for oral administration. Colesevelam hydrochloride is a high-capacity bile acid-binding molecule. Colesevelam hydrochloride is poly(a... |
| Active Ingredient | Colesevelam hydrochloride |
| Dosage Form | Tablet; For suspension |
| Route | Oral |
| Strength | 625mg; 1.875gm/packet; 3.75gm/packet |
| Market Status | Prescription |
| Company | Daiichi Sankyo |
For use, alone or in combination with an HMG-CoA reductase inhibitor, as adjunctive therapy to diet and exercise for the reduction of elevated LDL cholesterol in patients with primary hypercholesterolemia (Fredrickson Type IIa).
FDA Label
Cholestagel co-administered with a 3-hydroxy-3-methyl-glutaryl-coenzyme-A (HMG-CoA)-reductase inhibitor (statin) is indicated as adjunctive therapy to diet to provide an additive reduction in low-density-lipoprotein-cholesterol (LDL-C) levels in adult patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone.
Cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total cholesterol and LDL-C in adult patients with primary hypercholesterolaemia, in whom a statin is considered inappropriate or is not well tolerated.
Cholestagel can also be used in combination with ezetimibe, with or without a statin, in adult patients with primary hypercholesterolaemia, including patients with familial hypercholesterolaemia (see section 5. 1).
Colesevelam is a high capacity bile-acid binding molecule. Colesevelam binds to bile acids in the intestine which reduces the amount of bile acids that are returned to the liver via enterohepatic circulation. Clinical studies have demonstrated that elevated levels of total cholesterol (total-C), LDL-C, and apolipoprotein B (Apo B, a protein associated with LDL-C) are associated with an increased risk of atherosclerosis in humans. Similarly, decreased levels of high-density lipoprotein cholesterol (HDL-C) are associated with the development of atherosclerosis. Epidemiological investigations have established that cardiovascular morbidity and mortality vary directly with the levels of total-C and LDL-C, and inversely with the level of HDL-C. The combination of colesevelam and an HMG-CoA reductase inhibitor is effective in further lowering serum total-C and LDL-C levels beyond that achieved by either agent alone.
Anticholesteremic Agents
Substances used to lower plasma cholesterol levels. (See all compounds classified as Anticholesteremic Agents.)
C10AC04
C - Cardiovascular system
C10 - Lipid modifying agents
C10A - Lipid modifying agents, plain
C10AC - Bile acid sequestrants
C10AC04 - Colesevelam
Absorption
Not hydrolyzed by digestive enzymes and is not absorbed.
Route of Elimination
Excretion: In 16 healthy volunteers, an average of 0.05% of administered radioactivity from a single 14C-labeled colesevelam hydrochloride dose was excreted in the urine.
Not applicable (not hydrolyzed by digestive enzymes and not absorbed).
Colesevelam binds bile acids in the intestine and prevents their reabsorption. Colesevelam is not absorbed itself. The depletion of bile acid causes the upregulation of cholesterol 7-alpha-hydroxylase and conversion of cholesterol to bile acid. this increases the production and activity of hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase in the liver as well as an increase in the number of low density lipoprotein (LDL) receptors. This process clears LDL cholesterol from the blood. Serum triglyceride levels may increase or remain unchanged. The end result is increased clearance of LDL-cholesterol from the blood with decreased serum LDL-cholesterol.
API SUPPLIERS
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38605
Submission : 2023-07-18
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-05-01
Pay. Date : 2013-04-18
DMF Number : 22870
Submission : 2009-06-16
Status : Active
Type : II
NDC Package Code : 66499-0022
Start Marketing Date : 2008-07-03
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-01-13
Pay. Date : 2015-11-16
DMF Number : 30001
Submission : 2015-11-13
Status : Active
Type : II
NDC Package Code : 66499-0022
Start Marketing Date : 2008-07-03
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-02-12
Pay. Date : 2013-12-05
DMF Number : 26934
Submission : 2013-03-31
Status : Active
Type : II
Date of Issue : 2019-10-07
Valid Till : 2022-07-02
Written Confirmation Number : WC-0226
Address of the Firm :
NDC Package Code : 14593-829
Start Marketing Date : 2020-03-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-03-07
Pay. Date : 2013-02-20
DMF Number : 23378
Submission : 2009-12-16
Status : Active
Type : II
Date of Issue : 2022-09-30
Valid Till : 2025-08-04
Written Confirmation Number : WC-0127
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-08-04
Pay. Date : 2015-01-14
DMF Number : 28945
Submission : 2014-12-19
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37431
Submission : 2022-12-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27492
Submission : 2013-09-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23333
Submission : 2010-04-06
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Sweden
Brand Name : Cholestagel
Dosage Form : FILM COATED PILL
Dosage Strength : 625 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Norway
Brand Name : Cholestagel
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 625 mg
Packaging : Bottle of plastic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 625MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : RX
Registration Country : USA
Brand Name : COLESEVELAM HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 625MG
Packaging :
Approval Date : 2018-10-05
Application Number : 210889
Regulatory Info : RX
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : COLESEVELAM HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 625MG
Packaging :
Approval Date : 2020-09-02
Application Number : 200830
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : LODALIS
Dosage Form : POWDER FOR SUSPENSION
Dosage Strength : 3.75G/SACHET
Packaging :
Approval Date :
Application Number : 2432463
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : DISCN
Registration Country : USA
Brand Name : WELCHOL
Dosage Form : CAPSULE;ORAL
Dosage Strength : 375MG
Packaging :
Approval Date : 2000-05-26
Application Number : 21141
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : WELCHOL
Dosage Form : BAR, CHEWABLE;ORAL
Dosage Strength : 3.75GM
Packaging :
Approval Date : 2019-04-03
Application Number : 210895
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : COLESEVELAM HYDROCHLORIDE
Dosage Form : FOR SUSPENSION;ORAL
Dosage Strength : 3.75GM/PACKET
Packaging :
Approval Date : 2018-07-16
Application Number : 202190
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Norway
Brand Name : Cholestagel
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 625 mg
Packaging : Bottle of plastic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Coating Systems & Additives
Fillers, Diluents & Binders
Controlled & Modified Release
Direct Compression
Thickeners and Stabilizers
Lubricants & Glidants
Co-Processed Excipients
Granulation
Disintegrants & Superdisintegrants
Film Formers & Plasticizers
Taste Masking
Empty Capsules
Chewable & Orodispersible Aids
Vegetarian Capsules
API Stability Enhancers
Emulsifying Agents
Coloring Agents
Rheology Modifiers
Solubilizers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Market Place
